Literature DB >> 8641759

Sporadic invasion of cultured epithelial cells by Haemophilus influenzae type b.

P D Johnson1, F Oppedisano, V Bennett-Wood, G L Gilbert, R M Robins-Browne.   

Abstract

While working with an in vitro invasion assay, we observed that Haemophilus influenzae type b occasionally exhibits highly invasive behavior. The phenomenon is not inhibited by colchicine or cytochalasin but is dependent on the presence of supplemental CO2. We propose that sporadic invasiveness may correlate with the unknown events that precede Haemophilus influenzae type b bacteremia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641759      PMCID: PMC173880          DOI: 10.1128/iai.64.3.1051-1053.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Outer membrane protein subtypes of Haemophilus influenzae type b isolates causing invasive disease in Victoria, Australia, from 1988 to 1990.

Authors:  D A Clements; S J MacInnes; G L Gilbert
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

2.  Rifampicin prophylaxis for throat carriage of Haemophilus influenzae type b in patients with invasive disease and their contacts.

Authors:  G L Gilbert; S J MacInnes; I A Guise
Journal:  BMJ       Date:  1991-06-15

3.  Identification of a new locus involved in expression of Haemophilus influenzae type b lipooligosaccharide.

Authors:  G P Jarosik; E J Hansen
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

4.  Quantitative assessment of the ability of Escherichia coli to invade cultured animal cells.

Authors:  R M Robins-Browne; V Bennett-Wood
Journal:  Microb Pathog       Date:  1992-02       Impact factor: 3.738

5.  Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus.

Authors:  H de Lencastre; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  The gal locus from Haemophilus influenzae: cloning, sequencing and the use of gal mutants to study lipopolysaccharide.

Authors:  D J Maskell; M J Szabo; M E Deadman; E R Moxon
Journal:  Mol Microbiol       Date:  1992-10       Impact factor: 3.501

7.  Antibodies to Haemophilus influenzae type b outer membrane proteins in children with epiglottitis or meningitis and in healthy controls.

Authors:  P D Johnson; S J MacInnes; G L Gilbert
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

8.  Human microvascular endothelial tissue culture cell model for studying pathogenesis of Brazilian purpuric fever.

Authors:  F D Quinn; R S Weyant; M J Worley; E H White; E A Utt; E A Ades
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

9.  Clinical manifestations and outcome of Haemophilus influenzae type b disease.

Authors:  G L Gilbert; P D Johnson; D A Clements
Journal:  J Paediatr Child Health       Date:  1995-04       Impact factor: 1.954

10.  Carbon dioxide regulated secretion of the EaeB protein of enteropathogenic Escherichia coli.

Authors:  R Haigh; T Baldwin; S Knutton; P H Williams
Journal:  FEMS Microbiol Lett       Date:  1995-06-01       Impact factor: 2.742

View more
  3 in total

Review 1.  Role of pili in Haemophilus influenzae adherence and colonization.

Authors:  J R Gilsdorf; K W McCrea; C F Marrs
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

2.  Nontypeable Haemophilus influenzae carbonic anhydrase is important for environmental and intracellular survival.

Authors:  Jeroen D Langereis; Aldert Zomer; Hendrik G Stunnenberg; Peter Burghout; Peter W M Hermans
Journal:  J Bacteriol       Date:  2013-04-05       Impact factor: 3.490

3.  Comparative efficacies of different antibiotic treatments to eradicate nontypeable Haemophilus influenzae infection.

Authors:  Yukie Sekiya; Masahiro Eguchi; Masahiko Nakamura; Kimiko Ubukata; Satoshi Omura; Hidenori Matsui
Journal:  BMC Infect Dis       Date:  2008-02-07       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.